GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker

Just four months after promising a speedy review for using GlaxoSmithKline’s Zejula in late-line ovarian cancer, the FDA has come through with an OK. The approval arrived just ahead of GSK’s Q3 numbers, backing up R&D chief Hal Barron’s lofty ambitions for the PARP inhibitor.